Market Research Reports and Industry Reports

Diabetes Drugs Survey

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization, as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This report evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes in the future.

 1. Overview 9
 1.1 Statement of Report 9
 1.2 About this Report 9
 1.3 Scope of the Report 10
 1.4 Methodology 11
 1.5 Executive Summary 12
 
 2. Introduction 16
 2.1 Demographics of Diabetes 17
 2.1.1 Worldwide Diabetes 17
 2.1.2 U.S. Diabetes 20
 2.2 Economics of Diabetes 26
 2.2.1 Worldwide Costs of Diabetes 26
 2.2.2 Costs of Diabetes in the U.S. 27
 
 3. Understanding Diabetes 32
 3.1 Pre-Diabetes Syndrome 33
 3.2 Metabolic Syndrome 33
 3.2.1 Prevalence of Metabolic Syndrome 36
 3.2.2 Management of Metabolic Syndrome 37
 3.2.3 The Debate Regarding Metabolic Syndrome 37
 3.3 Diabetes and Inflammation 38
 3.4 Diagnosis of Diabetes Mellitus 39
 3.5 Progression of Diabetes 39
 3.6 Obesity and Diabetes 39
 3.7 Complications and Co-Morbidities in Type 2 Diabetes 41
 3.7.1 Preventing Complications and Co-Morbidities in Diabetes 45
 
 4. Pharmaceutical Industry and the Anti-Diabetes Drug Market 47
 4.1 The Worldwide Pharmaceutical Industry 47
 4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 47
 4.1.2 Global Pharmaceutical Market 49
 4.2 Overall Diabetes Drug Market Size and Growth 55
 4.2.2 Sales Forecast for the Global Anti-diabetes Drug Market 59
 4.3 Diabetic Medications Overview 61
 4.3.1 Recent Trends in Diabetic Drug Usage 63
 4.3.2 Market Influence Factors 65
 
 5. Non-Insulin Anti-Diabetes Products and Market 67
 5.1 Non-Insulin Anti-Diabetes Drug Market Drivers and Trends 70
 5.1.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs 71
 5.1.2 Latest Additions to the U.S. Non-Insulin Diabetes Drug Market 73
 5.1.3 GLP-1 Market Revenue, Market Share, Key Players 73
 5.1.4 DPP-4 Inhibitor Market Revenue, Market Share and Key Players 74
 5.1.5 SGLT-2 Inhibitor Market Revenue, Market Share and Key Players 76
 5.2 Sulfonylureas 76
 5.3 Meglitinides 77
 5.4 Biguanides 78
 5.5 Thiazolidinediones (TZDs) 79
 5.6 α-Glucosidase Inhibitors 81
 5.7 Amylin Analog 82
 5.8 GLP-1 (Glucagon-like Peptide) Analogs and Agonists/Incretin Mimetics 82
 5.8.1 Byetta (Exenatide) 83
 5.8.2 Bydureon (Exenatide LAR) 84
 5.8.3 Victoza (Liraglutide) 84
 5.8.4 Tanzeum (Albiglutide) 84
 5.8.5 Trulicity (Dulaglutide) 85
 5.9 DPP-IV Inhibitors 85
 5.9.1 Januvia (Sitagliptin) 87
 5.9.2 Onglyza (Saxagliptin) 87
 5.9.3 Tradjenta (Linagliptin) 87
 5.9.4 Galvus (Vildagliptin) 87
 5.9.5 Nesina (Alogliptin) 88
 5.9.6 Marizev (Omarigliptin) 88
 5.10 SGLT-2 Inhibitors 88
 5.10.1 Invokana (Canagliflozin) 89
 5.10.2 Farxiga (Dapagliflozin) 89
 5.10.3 Jardiance (Empagliflozin) 90
 5.10.4 Suglat (Ipragliflozin) 91
 5.10.5 Lusefi (Luseogliflozin) 91
 5.11 Fixed Dose Combination Therapies on the Market 91
 5.12 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce 93
 5.13 Comparisons of the Anti-Diabetes Drugs 93
 5.14 Non-Insulin Anti-Diabetes Products in the Pipeline 94
 5.14.1 Novel GLP-1 Agonists and Analogs 94
 5.14.2 Novel DPP-IV Inhibitors 97
 5.14.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors 99
 5.15 Emerging Anti-Diabetes Targets and Drugs in the Pipeline 100
 5.16 Novel Approaches to Finding New Drug Targets 104
 
 6. Insulin Markets 105
 6.1 Major Players and Market Share in the Insulin Market 107
 6.2 Patent Expirations 109
 6.3 Insulin Biosimilars 109
 6.3.1 Regulatory Avenues for Biosimilar Approval 110
 6.3.2 Insulin Biosimilars on the Market 110
 6.3.2.1 Abasaglar (formerly Abasria) and Basaglar 110
 6.3.2.2 Other Biosimilars 110
 6.3.2.3 Key Issues for Insulin Biosimilars 110
 6.4 Innovation Strategies 111
 6.5 Overview of Insulin Therapeutics on the Market 111
 6.5.1 Recommendations for Insulin Initiation and Administration 113
 6.6 Short-Acting Human Insulin Market 115
 6.7 Rapid-Acting Insulin Analog Market 117
 6.7.1 Ultra Fast-Acting Insulins in Development 118
 6.8 Intermediate-Acting Insulin Market 120
 6.9 Long-Acting Insulin Market 121
 6.9.1 Lantus-Sanofi’s Insulin Blockbuster 123
 6.9.2 Toujeo-Sanofi’s Bid to Maintain Insulin Market Share 124
 6.9.3 Levemir Market 124
 6.9.4 Tresiba Approved for the U.S. Market 125
 6.9.5 Lantus Biosimilars 126
 6.9.5.1 Abasaglar (formerly Abasria) and Basaglar 126
 6.9.5.2 Other Biosimilars 126
 6.10 Insulin Mixtures 127
 6.11 Pipeline Insulins in Development 128
 6.11.1 BIOD-531 (Biodel) 128
 6.11.2 Xultophy (Novo Nordisk) 128
 6.11.3 LixiLan (Sanofi) 128
 6.11.4 rHUPH20 and Insulin (Halozyme) 128
 6.11.5 FIAsp (Novo Nordisk) 129
 6.11.6 BIOD-238, BIOD-250, and BIOD-351 (Biodel) 129
 6.11.7 InsuPatch and InsuPad (Insuline Medical) 129
 6.11.8 MK-1293 130
 6.11.9 Smart Insulins 130
 6.12 Non-Invasive Insulin Delivery 130
 6.12.1 Inhaled Insulin 131
 6.12.1.1 Afrezza 132
 6.12.1.2 Dance Pharmaceuticals and Aerogen (Dance-501) 133
 6.12.1.3 A Chronicle of Inhaled Insulins 134
 6.12.2 Oral Insulin 135
 6.12.3 Transdermal Insulin 138
 6.13 Barriers for Non-Injected Insulin 139
 6.14 Patient Potential for Non-Injected Insulin 140
 6.15 Insulin Delivery Devices 140
 6.15.1 Insulin Pens 142
 6.15.2 Injections Aids 145
 6.15.2.1 Automatic Injectors 146
 6.15.2.2 Syringe Magnifiers 147
 6.15.2.3 Injection Ports 147
 6.15.3 Insulin Jet Injectors 148
 6.15.4 Insulin Pumps 148
 6.15.4.1 External Insulin Pumps 149
 6.15.4.2 Animas OneTouch Ping 152
 6.15.4.3 Animas Vibe 153
 6.15.4.4 Accu-Chek Combo Insulin Pump System (Roche) 153
 6.15.4.5 MiniMed Paradigm Real-Time Revel (Medtronic) 154
 6.15.4.6 MiniMed 530G with Enlite (Medtronic) 154
 6.15.4.7 Insulet Omnipod 154
 6.15.4.8 DANA IIS (Sooil) 155
 6.15.4.9 t:flex (Tandem Diabetes Care) 155
 6.15.4.10 t:slim (Tandem Diabetes Care) 155
 6.15.4.11 Snap (Asante) 155
 6.15.5 Insulin Infusion Sets 156
 6.15.6 Insulin Patch Pumps in Development or Only Available Outside the U.S. 157
 6.15.7 Implantable Insulin Pumps 159
 6.15.8 Insulin Pump Market Share 160
 6.15.9 Drivers of Demand for Pumps 161
 6.16 Market Forecasts for Insulin Administration Technologies 161
 
 7. Emerging Anti-Diabetes Technologies and Products 162
 7.1 Projections for the Anti-Diabetes Drug Market 162
 7.2 Artificial Pancreas 166
 7.2.1 MiniMed 530G System 167
 7.2.2 Animas Vibe System 167
 7.2.3 Next Generation Medtronic Artificial Pancreas Systems (MiniMed 640G) 167
 7.2.4 FDA’s Artificial Pancreas Guidance Document 168
 7.3 Insulin-Producing Cells 168
 7.3.1 Gene Therapy 169
 7.3.2 Cell Therapy Companies for Diabetes 170
 7.3.2.1 ViaCyte (formerly Novocell, Inc.) 170
 7.3.2.2 Sernova 170
 7.3.2.3 Semma Therapeutics 171
 7.4 Pre-Mixed Glucagon for Self-Treating Hypoglycemia 171
 7.5 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 171
 7.5.1 Xenical (Roche) 171
 7.5.2 Qsymia (Vivus) 171
 7.5.3 Belviq (Arena Pharmaceuticals) 171
 7.5.4 Contrave (Orexigen Therapeutics) 172
 7.5.5 Saxenda 172
 7.5.6 Anti-Obesity Drugs in Development 172
 7.6 Insulin and Anti-Diabetes Drug Combinations 172
 7.6.1 Xultophy (Novo Nordisk) 172
 7.6.2 LixiLan (Sanofi) 173
 
 8. Market Trends, Challenges and Strategic Options 174
 8.1 Overview 174
 8.2 Diabetes Drug Market Trends 174
 8.2.1 Overview 174
 8.2.2 Emergence of Therapeutics with Improved Administration Characteristics 174
 8.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics 176
 8.2.3 Increasing Prevalence of Obesity 176
 8.2.4 Consumer Preference Drives Product Development in Invasive Technology Segment 177
 8.3 Diabetes Mellitus Market Challenges 177
 8.3.1 Overview 177
 8.3.2 Patent Expirations 178
 8.3.3 Market Prospects of Inhalable Insulin 178
 8.4 Strategic Options 179
 8.4.1 Developing Countries are Key Markets for Growth 180
 8.4.2 Consumer-Driven Marketing Campaigns 181
 8.4.3 Strategies for Successful New Product Launches 181
 8.4.4 Collaborations and Strategic Alliances 182
 8.5 FDA Guidelines for Developing Anti-Diabetic Drugs 183
 8.6 Recent Industry Activity 183
 
 9. Company Profiles 187
 9.1 A. Menarini 187
 9.2 Abbott Laboratories 187
 9.3 Abbvie 191
 9.4 Amgen 191
 9.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) 192
 9.6 Animas (part of Johnson & Johnson) 192
 9.7 Asante 192
 9.8 Astellas Pharma, Inc. 192
 9.9 AstraZeneca PLC 193
 9.10 Bayer 194
 9.11 Becton, Dickinson and Company 196
 9.12 Biocon 197
 9.13 Biodel 198
 9.14 BodyMedia 198
 9.15 Boehringer Ingelheim 198
 9.16 Bristol Myers Squibb 199
 9.17 Cellnovo 199
 9.18 CeQur 199
 9.19 ConjuChem 199
 9.20 Daiichi Sankyo 200
 9.21 Dance Biopharm 200
 9.22 Debiotech 200
 9.23 DexCom 200
 9.24 Echo Therapeutics, Inc. 202
 9.25 Eli Lilly 203
 9.26 FIFTY50 Medical, Inc. 204
 9.27 Flamel Technologies 204
 9.28 Generex Biotechnology Corporation 204
 9.29 GlaxoSmithKline PLC 205
 9.30 Halozyme Therapeutics 205
 9.31 Insulet 205
 9.32 Insuline Medical Ltd. 206
 9.33 Intarcia Therapeutics, Inc. 206
 9.34 Janssen Research & Development 206
 9.35 Johnson & Johnson 207
 9.36 Kowa Pharmaceuticals 208
 9.37 Lexicon Pharmaceuticals 208
 9.38 MannKind Corporation 209
 9.39 Medipacs 209
 9.40 Medtronic 209
 9.41 Merck & Company, Inc. 210
 9.42 Mitsubishi Tanabe Pharma Corporation 211
 9.43 Novartis 211
 9.44 Novo Nordisk 211
 9.45 Oramed Pharmaceuticals 212
 9.46 Orexigen Therapeutics, Inc. 212
 9.47 Owen Mumford 213
 9.48 PhaseBio Pharmaceuticals 213
 9.49 Pfizer 213
 9.50 Prometheon Pharma 214
 9.51 Roche Diagnostics 214
 9.52 Sanofi 216
 9.53 Sernova 217
 9.54 Smiths Medical 217
 9.55 SOOIL Development 218
 9.56 Taisho Pharmaceuticals 218
 9.57 Takeda 218
 9.58 Tandem Diabetes Care, Inc. 218
 9.59 Theracos, Inc. 219
 9.60 Transdermal Specialties, Inc. 219
 9.61 Valeritas 219
 9.62 ViaCyte, Inc. (formerly Novocell) 219
 9.63 Vivus, Inc. 220
 9.64 vTv Therapeutics (formerly TransTech Pharma) 220
 9.65 Ypsomed Holding 220
 9.66 Zealand Pharma 220
 


List Of Tables

 Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2015 and 2035 18
 Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group),
 2015 and 2035 19
 Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013 19
 Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013 20
 Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013 22
 Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010 23
 Table 2.7: Cost of Diagnosed Diabetes in the U.S. 27
 Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes 29
 Table 2.9: Healthcare Utilization by Diabetic Patients 29
 Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome 34
 Table 3.2: Ethnic Specific Values for Waist Circumference in IDF’s Metabolic Syndrome Criteria 34
 Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome 34
 Table 3.4: Additional Metabolic Criteria for Research 36
 Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 42
 Table 3.6: Prevalence of Complications Among Patients with Diabetes 43
 Table 3.7: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes 44
 Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus 44
 Table 3.9: Major Causes of End-Stage Renal Disease 44
 Table 3.10: Clinical Recommendations for Adults with Diabetes 45
 Table 3.11: Laboratory Assessment of Diabetic Vascular Disease 45
 Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management 46
 Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014 47
 Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2014 47
 Table 4.3: Leading Therapy Classes for R&D, 2014 48
 Table 4.4: Leading Disease Indications for R&D, 2014 49
 Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012 49
 Table 4.6: Global Pharmaceutical Sales by Region and Country, 2013 and 2018 (estimated) and CAGR 2009-2013 and 2014-2018 (estimated) 50
 Table 4.7: World Pharmaceutical Sales Share by Region, 2013 51
 Table 4.8: Leading Ten Therapeutic Classes by Global Sales, 2010-2014 52
 Table 4.9: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2018 52
 Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2018 53
 Table 4.11: Leading Therapeutic Classes by U.S. Sales, 2010-2014 53
 Table 4.12: Top Selling Drugs Worldwide by Sales, 2014 53
 Table 4.13: Top Selling Drugs in the U.S. by Sales, 2014 54
 Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2014 54
 Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019 55
 Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019 55
 Table 4.17: Anti-Diabetic Therapy Markets, 2014 56
 Table 4.18: Top Ten Branded Anti-Diabetics by Sales Worldwide, 2014 59
 Table 4.19: Top Ten Branded Anti-Diabetics by Monthly Prescriptions Worldwide, 2014 59
 Table 4.20: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes 61
 Table 4.21: Summary of Glucose-Lowering Interventions as Monotherapy 62
 Table 5.1: Classes of Non-Insulin Hypoglycemic Agents 68
 Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014 69
 Table 5.3: Relative Efficacy of Diabetes Drugs 70
 Table 5.4: Worldwide Non-Insulin Anti-Diabetes Drug Market, 2012-2019 72
 Table 5.5: U.S. Non-Insulin Anti-Diabetes Drug Market, 2012-2019 72
 Table 5.6: Diabetes Drugs Approved for U.S. Market, 2014 and 2015 73
 Table 5.7: GLP-1 Drug Revenues in 2014 74
 Table 5.8: DPP-4 Inhibitor Revenues in 2014 75
 Table 5.9: SGLT-2 Inhibitor Revenues in 2014 76
 Table 5.10: Fixed-Dose Oral Anti-Diabetes Drug Combinations 92
 Table 5.11: GLP-1 Agonist Pipeline: Selected Drugs in Development 95
 Table 5.12: DPP-IV Inhibitor Pipeline: Selected Drugs in Development 98
 Table 5.13: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development 99
 Table 5.14: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development 99
 Table 5.15: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories 101
 Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2014 105
 Table 6.2: Worldwide Insulin Market, 2012-2019 106
 Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2014 106
 Table 6.4: U.S. Insulin Market, 2012-2019 106
 Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2014 107
 Table 6.6: Worldwide Insulin Market by Type (% Market Value), 2014 107
 Table 6.7: Worldwide Insulin Sales and Value Market Share by Company, 2014 107
 Table 6.8: U.S. Insulin Sales and Value Market Share by Company, 2014 108
 Table 6.9: Insulins on the U.S. Market 112
 Table 6.10: Pharmacokinetics of Therapeutic Insulins on the U.S. Market 113
 Table 6.11: Comparison of Recommendations from Existing Guidelines 115
 Table 6.12: Pharmacokinetics of Short-Acting Human Insulins 115
 Table 6.13: Short-Acting Human Insulin Worldwide Market Revenues, 2011-2014 116
 Table 6.14: Pharmacokinetics of Rapid-Acting Insulins 117
 Table 6.15: Rapid-Acting Insulin Worldwide Market Revenues, 2011-2014 118
 Table 6.16: Pharmacokinetics of Intermediate-Acting Insulins 120
 Table 6.17: Intermediate-Acting Human Insulin Worldwide Market Revenues, 2011-2014 120
 Table 6.18: Pharmacokinetics of Long-Acting Insulins 121
 Table 6.19: Long-Acting Insulin Worldwide Market Revenues, 2011-2014 122
 Table 6.20: Pharmacokinetics of Insulin Mixtures 127
 Table 6.21: A Comparison of Existing Insulin Delivery Devices 141
 Table 6.22: Insulin Pens 143
 Table 6.23: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018 145
 Table 6.24: Injection Aids 146
 Table 6.25: Jet Injectors 148
 Table 6.26: Control Averages by Treatment 149
 Table 6.27: Reduced Risk for Various Diseases When Blood Glucose is Near Normal 149
 Table 6.28: Leading Insulin Pump Manufacturers 150
 Table 6.29: Comparison of Current External Insulin Pumps on the Market 150
 Table 6.30: Insulin Infusion Sets 156
 Table 6.31: Worldwide Insulin Pump Market, 2013-2019 160
 Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies 163
 Table 7.2: Cells of the Pancreas 169
 Table 8.1: BRIC Countries, Percentage of GDP Spent on Healthcare, 2013 180
 


List Of Figures

 Figure 2.1: Worldwide Diabetes Cases, 2015 and 2035 17
 Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013 18
 Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years,
 1980-2012 21
 Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012 22
 Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013 22
 Figure 2.6: Percentage of U.S. Adults Diagnosed Diabetes by State, 2013 24
 Figure 2.7: Number of Deaths from Diabetes by Age in the U.S., 2013 25
 Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S., 2013 25
 Figure 2.9: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD),
 2013 26
 Figure 2.10: How Diabetes Dollars are Spent in the U.S. 28
 Figure 3.1: Maintenance of Normal Blood Sugar Levels 32
 Figure 3.2: Prevalence of Self-Reported Obesity (BMI ³ 30) Among U.S. Adults, 2013 40
 Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2012 40
 Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 1999-2012 41
 Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2012-2019 60
 Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2012-2019 60
 Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012 62
 Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Market by Volume, 2014 64
 Figure 5.1: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2014 71
 Figure 5.2: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2014 71
 Figure 5.3: GLP-1 Market Share by Brand, 2014 73
 Figure 5.4: GLP-1 Market Share of Key Players, 2014 74
 Figure 5.5: DPP-4 Inhibitor Market Share by Brand, 2014 75
 Figure 5.6: DPP-4 Inhibitor Market Share of Key Players, 2014 76
 Figure 5.7: Overview of GLP-1 and Blood Glucose 82
 Figure 5.8: Overview of DPP-4 Inhibitors and Blood Glucose 86
 Figure 5.9: SGLT-2 Inhibitor Mechanism of Action 89
 Figure 6.1: Worldwide Insulin Market Share (Value), 2014 108
 Figure 6.2: U.S. Insulin Market Share (Value), 2014 108
 Figure 6.3: Short-Acting Human Insulin Worldwide Market Share by Company, 2014 116
 Figure 6.4: Rapid-Acting Insulin Worldwide Market Share by Company, 2014 118
 Figure 6.5: Intermediate-Acting Human Insulin Worldwide Market Share by Company, 2014 121
 Figure 6.6: Long-Acting Insulin Worldwide Market Share by Company, 2014 122
 Figure 6.7: Market Share of Basal Insulins in Emerging Markets, 2014 123
 Figure 6.8: Global Sales of Lantus, 2005-2014 124
 Figure 6.9: Global Sales of Levemir, 2011-2014 125
 Figure 6.10: Insulin Pump Market Share, 2014 160


TD Systems Limited Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Systems Limited Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

TD Securities Inc Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Securities Inc Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

TD Securities USA) LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Securities USA) LLC Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

TD Systems Limited Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Systems Limited Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

TD Securities Inc Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Securities Inc Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

TD Securities USA) LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

TD Securities USA) LLC Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 4995
  • Site Licence    $ 9990
  • Enterprise Wide Licence    $ 14985
$ 4995

Reports Details

Published Date : Jan 2016
No. of Pages :220
Country :Global
Category :Healthcare
Publisher :TriMark Publications, LLC
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment